October
01
  10:47:42 PM

Nitschke makes headlines again

Dr Philip Nitschke, founder of euthanasia group Exit International, made headlines yet again this week when he announced that he will import the suicide drug Nembutal to Australia. He has said that he intends to exploit a “loophole” in the Therapeutic Goods Administration’s regulations on medicine to import the drug for a woman in South Australia. However, as a anti-euthanasia campaigner Paul Russell suggests, it may be a lot of hot air – the “loophole” to which Nitschke refers may not actually exist.

Nitschke says the TGA has approved the importation – which it has not – and that he intends to import Nembutal under a provision in the TGA’s guidelines for unregistered medicines. These guidelines explicitly state that medicines in this category must be for treating life-threatening diseases with medicines which have not undergone formal clinical trials. While Nembutal was once used as a sedative, its primary function at present is to euthanase animals and humans. ~ Sydney Morning Herald, Sep 27; Careful!, Sep 27; London Telegraph, Sep 26




 

 Search BioEdge

 Subscribe to BioEdge newsletter
rss Subscribe to BioEdge RSS feed

 Best of the web

 Recent Posts
Indian surrogate for US woman dies in Gurjarat
18 May 2012
Do reproductive rights survive gender reassignment?
19 May 2012
South African activists begin euthanasia campaign
19 May 2012
70 assisted suicides in Washington state in 2011
19 May 2012
Would-be grandparents pay for their daughters’ egg freezing
19 May 2012

 Tags
informed consent, Down syndrome, organ transplants, clinical trials, law, bioethics, embryonic stem cells, IVF, China, stem cells, assisted suicide, Australia, euthanasia, UK, sex selection, surrogacy, suicide, neuroscience, organ donation, research, human drama, India, sperm donation, US, organ trafficking, Canada, abortion, commercialization, genetic testing, Netherlands,